Louvain-La-Neuve, Belgium, 27 August 2015 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces its consolidated results for the first half of 2015.

Business Highlights

Strong Proton Therapy and Other Accelerators order intake in H1, up 86% to EUR 110 million from the same period in 2014, comprising three Proteus®ONE* and three Proteus®PLUS systems and six accelerators

Record period-end backlog for Proton Therapy and Other Accelerators of EUR 303.2 million, up 56% YoY, 25% of which is Proteus®ONE orders, demonstrating the growing importance of single room compact solutions where IBA has a unique competitive advantage

Steadily growing Proton Therapy Services backlog to be recognized over time, now amounting to EUR 506.6 million, up 24% YoY due to the strong capture rate with new equipment orders

Dosimetry continues to show strongly improved performance with revenues growing 19.3% to EUR 26.8 million compared to EUR 22.5 million in the same period last year and backlog remaining strong at EUR 17.8 million

Philips collaboration bearing fruit with three Proteus®ONE orders signed in the UK with Proton Partners International

Strategic alliance signed with Toshiba Corporation for Proteus®ONE in Japan and advancing carbon therapy in the rest of the world

Financial Highlights

Total Group revenue of EUR 121.0 million for the first six months of 2015, up 23.3% (H1 2014: EUR 98.2 million)

REBIT up 30.8% to EUR 12.6 million with margin at 10.4%, in line with guidance

Reported net profit of EUR 14.4 million, up by 94.2% YoY with margin increase to 11.9% from 7.6%

2015 top line guidance increased from "above 10%" to 15-20% revenue growth for the year

Post Period End Highlight

Completion of the divestiture of IBA Molecular North America, Inc. (IBAM NA) to Illinois Health and Science (IHS). The transaction is not expected to have a significant impact on IBA's 2015 P&L but will generate cash proceeds of approximately EUR 10 million for IBA during the third quarter of 2015

Olivier Legrain, Chief Executive Officer of IBA, commented: "IBA has had a strong first half underpinned by a very buoyant global proton therapy environment. As the only company in the world able to convincingly offer both multi-room and compact single-room proton therapy systems, I am pleased to see that both solutions have seen such strong performance despite growing competition, demonstrating the broad appeal of IBA's proton therapy offering.

"We are also pleased to see restored growth in Dosimetry as well as that Services now represent a third of proton therapy revenues, and confirming it as an important recurring revenue driver.

"We expect the momentum across the business to continue in the second half, especially in the proton therapy market, leading us to be confident in increasing our 2015 guidance to 15-20% top line growth from the 10% average previously stated and we confirm a trend towards 30% dividend payout."

Conference Call Information:

IBA will host a conference call and webcast today at 2pm CEST / 1pm BST / 8am EDT. Olivier Legrain, Chief Executive Officer, and Jean-Marc Bothy, Chief Financial Officer, will host the call which will be conducted in English. The conference call will be webcast live and can be accessed on the investor page of the IBA website at: www.iba-worldwide.com/?page=investor-relations. If you would like to participate in the Q&A, please dial (PIN code 21347202#):

Belgium: +32 2 404 03 05

UK: +44 207 750 9926

NL: +31 207 133 488

LU: +352 278 601 66

US: +1 914 885 0779

FR: +33 172 040 033

The webcast presentation will be available on the Company's website shortly after the call.

Financial calendar

Third Quarter business update November 17, 2015

Full Year results 2015 March 24, 2016

Read the full Half Year 2015 press release

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1 100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

*

Proteus®ONE is the brand name of a new configuration of the Proteus® 235.

For further information please contact:

IBA

Jean-Marc Bothy
Chief Financial Officer
Tel: +32 10 47 58 90

Thomas Ralet
Vice-President Corporate Communication
+32 10 47 58 90
communication@iba-group.com


For media and investor enquiries:

Consilium Strategic Communications
Amber Fennell, Matthew Neal and Ivar Milligan
+44 (0)20 3709 5700
IBA@consilium-comms.com

Rx Communications Group (US)

Melody Carey
+1 917 322 2571
mcarey@RxIR.com

View PDF: http://www.iba-worldwide.com/uploads/articles/article_en_pdf/258/PR-IBA_Half-Year-2015-Results_EN-27082015.pdf